V 158866

Drug Profile

V 158866

Alternative Names: V-158866

Latest Information Update: 24 Aug 2015

Price : $50

At a glance

  • Originator Vernalis
  • Class Analgesics
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Neuropathic pain; Pain

Most Recent Events

  • 24 Aug 2015 Suspended - Phase-I for Pain in United Kingdom (PO)
  • 24 Aug 2015 Suspended - Phase-II for Neuropathic pain in USA (PO)
  • 20 Aug 2015 Efficacy and adverse events data from a phase II trial in Neuropathic pain released by Vernalis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top